Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Shares Issued (2019 - 2025)

BridgeBio Pharma's Shares Issued history spans 7 years, with the latest figure at $13.2 million for Q4 2025.

  • For Q4 2025, Shares Issued rose 363.9% year-over-year to $13.2 million; the TTM value through Dec 2025 reached $27.7 million, up 658.62%, while the annual FY2025 figure was $27.7 million, 658.62% up from the prior year.
  • Shares Issued for Q4 2025 was $13.2 million at BridgeBio Pharma, up from $11.3 million in the prior quarter.
  • Across five years, Shares Issued topped out at $446.4 million in Q4 2023 and bottomed at -$274.2 million in Q2 2024.
  • The 5-year median for Shares Issued is $2.2 million (2021), against an average of $25.6 million.
  • The largest YoY upside for Shares Issued was 16401.16% in 2023 against a maximum downside of 14460.25% in 2023.
  • A 5-year view of Shares Issued shows it stood at -$3.8 million in 2021, then surged by 228.24% to $4.9 million in 2022, then skyrocketed by 9010.47% to $446.4 million in 2023, then tumbled by 99.36% to $2.8 million in 2024, then soared by 363.9% to $13.2 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Shares Issued are $13.2 million (Q4 2025), $11.3 million (Q3 2025), and $3.2 million (Q1 2025).